This medication is commonly used for managing conditions involving elevated pressure within the eye.

What Альфаган Р Treats: Main Uses and Benefits

This medication is generally used to help manage conditions characterized by high pressure inside the eye, including Open-Angle Glaucoma and Ocular Hypertension. The primary therapeutic benefit provided contributes to achieving a reduction of this pressure, which is relevant for easing the overall symptom load related to high pressure.

The therapeutic objective is to support the maintenance of visual capacity and optic nerve health in high-risk individuals. By controlling the pressure, the medication assists with maintaining functional stability for the optic nerve, helping with slowing the progression of visual impairment.

“This treatment is commonly applied when supportive symptom management is appropriate for ongoing support in managing chronic eye pressure.”

Alphagan P is commonly used in diverse clinical settings, serving as either a single initial therapy (monotherapy) or as adjunctive therapy when additional symptomatic support is needed. Its utility as a relevant alternative is considered applicable for patients with certain systemic health challenges, such as cardiac or respiratory concerns, in situations involving a heightened systemic burden.

---

Quick Fact: Relief for Asymptomatic Ocular Pressure

This medication is primarily used to help manage the risk associated with asymptomatic ocular pressure elevation—a critical clinical sign that often presents without patient-perceived discomfort, yet is commonly managed through a specialized therapeutic approach.

Regulatory References

1. NIH MedlinePlus overview of Brimonidine Ophthalmic

The eligibility for Альфаган Р (Brimonidine Tartrate) is strictly defined by regulatory documents, distinguishing between populations where use is allowed, restricted, or absolutely prohibited.

Contraindicated Populations

The medicine must not be used in the following populations:

• Neonates and Infants (children younger than 2 years old).
• Patients receiving Monoamine Oxidase (MAO) inhibitor therapy.
• Patients with a known hypersensitivity to brimonidine tartrate or any component of the formulation.

Age and Condition Restrictions

Population Group	Regulatory Status
Children 2 years and above	Use with Caution due to potential for somnolence; close monitoring is required.
Pregnant Women	Use only if the potential benefit justifies the potential risk to the fetus; safety is not established.
Breastfeeding Women	Not recommended for use during lactation.
Comorbidities	Caution is required for patients with severe cardiovascular disease, depression, cerebral/coronary insufficiency, and certain vascular disorders (e.g., Raynaud’s phenomenon).
Organ Function	Caution is advised for patients with hepatic or renal impairment, as safety data are not established.

Adults and older adults are the primary eligible population for the drug's labeled indication.

Interactions with other medicines and products

This section outlines the officially documented interaction patterns for brimonidine tartrate (the active ingredient in Альфаган Р) as specified in government regulatory labeling.

Formal Contraindications and Prohibitions

Co-administration with Monoamine Oxidase (MAO) Inhibitors is formally contraindicated by regulatory authorities due to the potential for interference with brimonidine's systemic metabolism.

Additionally, co-administration with certain antidepressants that affect noradrenergic transmission, such as Tricyclic Antidepressants and Mianserin, is generally prohibited as these substances may potentially interfere with or reduce the intended pressure-lowering effect.

---

Pharmacodynamic and Systemic Effects

Central Nervous System (CNS) Depressants, including alcohol, barbiturates, opioids, and sedatives, are documented to have an additive or potentiating effect on CNS depression when co-administered with brimonidine.

Caution is advised when using antihypertensives or cardiac glycosides concomitantly, as official labeling notes the possibility of additive effects on systemic blood pressure and pulse rate, which may result in increased hypotension.

Agents that affect the metabolism and uptake of circulating amines, such as reserpine, may potentially blunt the ocular hypotensive response to brimonidine.

---

Administration Timing and Special Considerations

When using other topical ophthalmic products, the regulatory instruction requires that they must be administered at least 5 to 15 minutes apart from brimonidine drops. Brimonidine's interaction profile has not been studied in patients with significant hepatic or renal impairment, necessitating caution in these populations.

How Альфаган Р Works

Альфаган Р (brimonidine tartrate) exerts its action through the mechanism of agonism at the alpha2-adrenergic receptors.

Upon administration, brimonidine tartrate selectively targets and binds to the alpha2-adrenergic receptors located on the ciliary body within the eye. Receptor binding activates the associated intracellular G-protein signaling cascade. This alpha2-mediated signaling leads to a functional reduction in the production of aqueous humor by the ciliary epithelium, modulating the inflow of fluid into the anterior chamber.

Simultaneously, the agonism of these receptors facilitates a secondary system-level physiological consequence: the increase of aqueous humor outflow through the uveoscleral pathway. The combined modulation of both aqueous humor production (decreasing inflow) and uveoscleral outflow (increasing clearance) defines its mechanism of physiological modulation.

Official Administration Guidelines

Альфаган Р is administered as an ophthalmic solution, meaning it is applied topically to the eye using the dropper bottle.

Dosing and Schedule

The recommended dose is one drop in the affected eye(s) three times daily. To ensure consistent therapeutic action, the three daily doses should be spaced out to be administered approximately 8 hours apart.

Administration Procedure

When applying the eye drops, the following procedural steps are typically observed:

• Maintain Sterility: Do not allow the tip of the dispensing container to touch the eye or any surrounding surfaces. Contact can contaminate the solution, which may lead to serious eye injury or infection.
• Contact Lenses: Soft contact lenses must be removed before using this medication. A wait time of at least 15 minutes is required before reinserting soft contact lenses after the drop has been administered.
• Concomitant Products: If another topical eye product is being used at the same time, the different products must be instilled at least 5 minutes apart.

Missed Dose

If a dose is missed, it should be applied as soon as the patient remembers. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular dosing schedule should be continued. A double dose should not be used to attempt to catch up on a missed dose.

Research Evidence / Overview of studies for Альфаган Р

Evidence for Use as Initial Treatment (Monotherapy)

Research was derived from Randomized Controlled Trials (RCTs). These study designs were used in trials where participants were randomly assigned to different groups, often comparing Brimonidine against other topical ocular agents. Research primarily examined outcomes related to high pressure inside the eye, which is a condition characterized by functional limitations.

These trials focused on adults (18 years and older) diagnosed with Open-Angle Glaucoma or Ocular Hypertension. Researchers monitored the change in intraocular pressure (IOP) from the start of the study across different times of the day. The findings describe patterns observed in these studies, reporting that the measurement endpoint was associated with the medication. Additionally, regulatory trials compared the specific formulation known as Альфаган Р against the original Brimonidine solution to report its equivalence in these IOP measurements.

---

Evidence for Use as Add-on Treatment (Adjunctive Therapy)

Studies have also explored the use of this eye drop in situations where the initial single-agent therapy, such as a prostaglandin analog, was observed in trials to be not sufficient for pressure regulation. These were often structured as "Add-on" Trials where the medication was evaluated in adult patients whose IOP was considered uncontrolled despite their current treatment. Research evaluated whether adding Brimonidine was associated with further changes in IOP measurements.

---

Research in Special Populations, Including Children

Research has explored studies involving pediatric patients starting at the age of two, which was evaluated in specific trials. These were often multicenter studies where researchers monitored IOP measurements and, critically, outcomes related to systemic or functional imbalance. Specific attention was observed in the subgroups of children under six years old and those with a low body weight (under 20 kg).

Studies reported varied IOP measurements in the pediatric study populations. Trials described the observation of a higher frequency of findings related to the central nervous system, such as somnolence and lethargy, primarily in these younger, lower-weight subgroups. Due to these reported patterns, the data for certain groups, particularly the very young, are still emerging regarding the long-term outcomes or the demonstration of equivalence in IOP measurements compared to adults.

Common questions about Альфаган Р (FAQ)

Q: How long will one bottle of Alphagan P usually last me?

According to official product information, the eye drops should be discarded 28 days after you first open the bottle. This guidance is provided to help maintain the quality and sterility of the solution. The product is typically supplied in bottle sizes such as 5 mL or 10 mL.

---

Q: How soon after I start using the drops should I expect my eye pressure to drop?

Official information from clinical studies indicates that the effect of the medication to lower eye pressure is generally expected to be at its greatest approximately two hours after the drops are administered. This measurement reflects the time of the drug’s intended therapeutic effect.

---

Q: What are the most common side effects of Alphagan P?

Based on regulatory documentation summarizing clinical trials, the most common adverse reactions occurred in approximately 10% to 20% of patients. These included local effects affecting the eye, such as allergic conjunctivitis (eye allergy), conjunctival hyperemia (redness of the eye), and eye pruritus (itching).

---

Q: Can I use these drops if I am pregnant or breastfeeding?

Regulatory information advises that the medication should be used during pregnancy only if the potential benefit is determined to justify the potential risk to the fetus. For breastfeeding women, the medication is not recommended for use during lactation according to the official label.

---

Q: What is the difference between this specific product (Альфаган Р) and the original Alphagan drops?

The official product information notes that this specific formulation contains a unique preservative called Purite. This preservative is different from the one used in the original formulation and is included because it may improve local tolerability for some patients.

---

Q: What drug classes are prohibited or contraindicated with Alphagan P?

The medicine is formally contraindicated in patients who are currently receiving therapy with Monoamine Oxidase (MAO) Inhibitors. Official documentation also advises caution regarding co-administration with other drug classes, including Tricyclic Antidepressants and other Central Nervous System (CNS) depressants.

How to Store and Dispose of ALPHAGAN P (Brimonidine Tartrate)

The storage and disposal of ALPHAGAN P must strictly follow regulatory standards to ensure product integrity and safety.

Storage Requirements

• Temperature: Store the solution at Controlled Room Temperature, specifically between 15 C to 25 C (59 F to 77 F).
• Handling: The medication must be protected from freezing. To prevent contamination, do not allow the bottle tip to touch the eye or any surface, and replace the cap immediately after use.
• Stability: Do not use the solution if it changes color or becomes cloudy.
• Child Safety: Keep the product out of the reach of children.

Disposal Instructions

Do not use outdated portions of the product. Unused or expired medication must be properly disposed of according to local regulatory guidelines.